Literature DB >> 21357890

Lymphangioleiomyomatosis: what do we know and what are we looking for?

S Harari1, O Torre, J Moss.   

Abstract

Lymphangioleiomyomatosis (LAM) is a rare disease characterised by proliferation of abnormal smooth muscle-like cells (LAM cells) leading to progressive cystic destruction of the lung, lymphatic abnormalities and abdominal tumours. It affects predominantly females and can occur sporadically or in patients with tuberous sclerosis complex. This review describes the recent progress in our understanding of the molecular pathogenesis of the disease and LAM cell biology. It also summarises current therapeutic approaches and the most promising areas of research for future therapeutic strategies.

Entities:  

Mesh:

Year:  2011        PMID: 21357890      PMCID: PMC3386525          DOI: 10.1183/09059180.00011010

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  128 in total

1.  Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways.

Authors:  Chia-Ling Gau; Juran Kato-Stankiewicz; Chen Jiang; Susie Miyamoto; Lea Guo; Fuyuhiko Tamanoi
Journal:  Mol Cancer Ther       Date:  2005-06       Impact factor: 6.261

2.  The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment.

Authors:  Jay H Ryu; Joel Moss; Gerald J Beck; Jar-Chi Lee; Kevin K Brown; Jeffrey T Chapman; Geraldine A Finlay; Eric J Olson; Stephen J Ruoss; Janet R Maurer; Thomas A Raffin; Hannah H Peavy; Kevin McCarthy; Angelo Taveira-Dasilva; Francis X McCormack; Nilo A Avila; Rosamma M Decastro; Susan S Jacobs; Mario Stylianou; Barry L Fanburg
Journal:  Am J Respir Crit Care Med       Date:  2005-10-06       Impact factor: 21.405

3.  Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.

Authors:  Klaus Mross; Joachim Drevs; Marianne Müller; Michael Medinger; Dieter Marmé; Jürgen Hennig; Bruno Morgan; David Lebwohl; Eric Masson; Yu-Yun Ho; Clemens Günther; Dirk Laurent; Clemens Unger
Journal:  Eur J Cancer       Date:  2005-06       Impact factor: 9.162

4.  Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: a tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis.

Authors:  Nisreen El-Hashemite; Victoria Walker; David J Kwiatkowski
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 12.701

5.  Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis.

Authors:  Toshio Kumasaka; Kuniaki Seyama; Keiko Mitani; Sanae Souma; Satoko Kashiwagi; Akira Hebisawa; Teruhiko Sato; Hajime Kubo; Kiyoshi Gomi; Kazutoshi Shibuya; Yoshinosuke Fukuchi; Koichi Suda
Journal:  Am J Surg Pathol       Date:  2005-10       Impact factor: 6.394

6.  Cross-talk between tuberin, calmodulin, and estrogen signaling pathways.

Authors:  Brian York; Dingyuan Lou; Reynold A Panettieri; Vera P Krymskaya; Thomas C Vanaman; Daniel J Noonan
Journal:  FASEB J       Date:  2005-04-25       Impact factor: 5.191

7.  Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.

Authors:  Li Ma; Zhenbang Chen; Hediye Erdjument-Bromage; Paul Tempst; Pier Paolo Pandolfi
Journal:  Cell       Date:  2005-04-22       Impact factor: 41.582

8.  Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex.

Authors:  Mark Nellist; Ozgur Sancak; Miriam A Goedbloed; Christan Rohe; Diana van Netten; Karin Mayer; Aimee Tucker-Williams; Ans M W van den Ouweland; Dicky J J Halley
Journal:  Eur J Hum Genet       Date:  2005-01       Impact factor: 4.246

Review 9.  [Successful therapy of a postpartum lymphangioleiomyomatosis. Case report and literature review].

Authors:  J Zahner; F Borchard; H Fischer; W Schneider
Journal:  Schweiz Med Wochenschr       Date:  1994-09-17

10.  Bone mineral density in lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-Dasilva; Mario P Stylianou; Carolyn J Hedin; Olanda Hathaway; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2004-10-01       Impact factor: 21.405

View more
  18 in total

Review 1.  The lymphatic vasculature in disease.

Authors:  Kari Alitalo
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

2.  Lymphangioleiomyomatosis: current and future.

Authors:  Maria Mavroudi; Paul Zarogoulidis; Nikolaos Katsikogiannis; Kosmas Tsakiridis; Haidong Huang; Antonios Sakkas; Anastasios Kallianos; Aggeliki Rapti; Eirini Sarika; Ilias Karapantzos; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

3.  Adolescent form of sporadic lymphangioleiomyomatosis (S-LAM).

Authors:  S M Restrepo-Gualteros; C E Rodriguez-Martinez; L E Jaramillo-Barberi; A F Lopez-Cadena; G Nino
Journal:  Allergol Immunopathol (Madr)       Date:  2014-05-01       Impact factor: 1.667

4.  Sporadic lymphangioleiomyomatosis with bloody sputum as an initial symptom: A case report and review of the literature.

Authors:  Kai Wu; Hui-Yu Lu
Journal:  Exp Ther Med       Date:  2015-03-31       Impact factor: 2.447

Review 5.  Tuberous Sclerosis Complex: new criteria for diagnostic work-up and management.

Authors:  Sharon Samueli; Klaus Abraham; Anastasia Dressler; Gudrun Groeppel; Constanze Jonak; Angelika Muehlebner; Daniela Prayer; Andreas Reitner; Martha Feucht
Journal:  Wien Klin Wochenschr       Date:  2015-04-10       Impact factor: 1.704

6.  Inactivation of Tsc2 in Mesoderm-Derived Cells Causes Polycystic Kidney Lesions and Impairs Lung Alveolarization.

Authors:  Siying Ren; Yongfeng Luo; Hui Chen; David Warburton; Hilaire C Lam; Larry L Wang; Ping Chen; Elizabeth P Henske; Wei Shi
Journal:  Am J Pathol       Date:  2016-10-18       Impact factor: 4.307

Review 7.  Pulmonary Hypertension and Cancer: Etiology, Diagnosis, and Management.

Authors:  Fatima A Ballout; Ahmad S Manshad; Tochukwu M Okwuosa
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-06

8.  In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor.

Authors:  Ling Gao; Michael M Yue; Jennifer Davis; Elisabeth Hyjek; Lucia Schuger
Journal:  Virchows Arch       Date:  2014-02-26       Impact factor: 4.064

9.  Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis.

Authors:  Xiaoxiao Gu; Jane J Yu; Didem Ilter; Nickolas Blenis; Elizabeth Petri Henske; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-27       Impact factor: 11.205

10.  Detection of low-prevalence somatic TSC2 mutations in sporadic pulmonary lymphangioleiomyomatosis tissues by deep sequencing.

Authors:  Atsushi Fujita; Katsutoshi Ando; Etsuko Kobayashi; Keiko Mitani; Koji Okudera; Mitsuko Nakashima; Satoko Miyatake; Yoshinori Tsurusaki; Hirotomo Saitsu; Kuniaki Seyama; Noriko Miyake; Naomichi Matsumoto
Journal:  Hum Genet       Date:  2015-11-12       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.